Scarica l'app Stockscreener
1.97
3.43%
-0.07
Dopo l'orario di chiusura:
1.98
0.01
+0.51%
Compass Therapeutics Inc Borsa (CMPX) Ultime notizie
Compass Therapeutics eyes FDA path after Tovecimig trial win - MSN
Compass Therapeutics (NASDAQ: CMPX) investors back board, auditor and pay in 2026 votes - Stock Titan
CMPX: Lead oncology asset tovecimig nears FDA filing after strong BTC trial results; multiple catalysts ahead - TradingView
Compass Therapeutics, Inc. (CMPX) Latest Stock News & Headlines - Yahoo Finance
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win - MarketBeat
CMPX News | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Citizens reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Nigeria
CMPX Stock Chart | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
Piper Sandler Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Stifel reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Canada
Number of shareholders of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
CMPX Q1 2026 Earnings: Narrow EPS Beat Drives Positive Stock ReactionTrough Earnings Signal - thelegaladvocate.com
Compass Therapeutics to Participate in Upcoming June Investor Events - Investing News Network
Biotech Compass Therapeutics to present at Jefferies and Goldman Sachs events - Stock Titan
Compass Therapeutics (CMPX) Breaks Above Support: What’s Driving the 4.6% MoveStrangle Setup - newsline.com
CMPX Q1 2026 Earnings: Narrowed Loss Beats Estimates, Stock Surges 7.25%Forward Guidance Trends - newsline.com
Compass Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Biotech’s Pipeline ProgressNegative Surprise Momentum - newsline.com
Compass Therapeutics reports phase 1 data for CTX-8371 By Investing.com - Investing.com South Africa
Compass Therapeutics reports phase 1 data for CTX-8371 - Investing.com UK
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting - Investing News Network
Compass Therapeutics Announces Promising Phase 1 Results for CTX-8371, Innovative Dual Checkpoint Blocker in Advanced Malignancies - Quiver Quantitative
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc.CMPX - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass ... - Caledonian Record
CMPX: Lead bispecific antibody shows strong efficacy in BTC; FDA submission and pipeline advances ahead - TradingView
Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M - Yahoo Finance
Compass Therapeutics (CMPX) price target decreased by 26.39% to 10.11 - MSN
5 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
Compass Therapeutics(CMPX) Stock Options Chain | Quotes & News - Moomoo
Compass Therapeutics’s stock crashes after OS miss in BTC trial - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-13 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Reach Out | NDAQ:CMPX | Press Release - Stockhouse
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - FinancialContent
TradingKey - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-05-12 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Shareholders to Learn More About the Investigation | NDAQ:CMPX | Press Release - Stockhouse
Compass Therapeutics to Participate in Upcoming May Investor Events - The Manila Times
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewir - The National Law Review
CMPX (Compass Tx) shares surge 3% as biotech firm essentially meets Q1 loss expectations.Trader Community Insights - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
LifeSci Capital Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):